Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can stress tests reveal hidden heart damage in sickle cell patients?

NCT ID NCT05583721

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why the heart gets damaged in people with sickle cell disease. Researchers will use special PET scans to measure blood flow to the heart during rest and stress. They will compare results from 40 young adults—some with sickle cell disease and some without—to see if reduced blood flow is linked to heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 21 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Stratum A: Sickle cell patients with diastolic dysfunction * 18 to 21 years of age * Black * Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes * Three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography) Inclusion Criteria - Stratum B: Sickle cell patients without diastolic dysfunction * 18 to 21 years of age * Black * Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes * Two or less abnormal diastolic parameters Inclusion Criteria - Stratum C: Healthy controls * 18 to 21 years of age * Black * Two or less abnormal diastolic parameters Exclusion Criteria - Stratum A: * Recent hospitalization for vaso-occlusive pain crisis or acute chest syndrome in last 4 weeks * Blood transfusion in the last 3 months * Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina * Individuals with history of VT/VF or SVT * Previous cardiac surgery * Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect) * Stenotic valvular disease or left main coronary artery stenosis * History of myo/pericarditis * Left ventricle systolic dysfunction * Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency) * History of sinus node dysfunction or high grade AV nodal block * History of aborted sudden cardiac death or cardiac arrest * Current seizure disorder on AED * Pregnant/Breast-feeding * Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised. Exclusion Criteria - Stratum B: * Diagnosed with three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography) * Recent hospitalization for vaso-occlusive pain crisis or acute chest syndrome in last 4 weeks * Blood transfusion in the last 3 months * Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina * Individuals with history of VT/VF or SVT * Previous cardiac surgery * Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect) * Stenotic valvular disease or left main coronary artery stenosis * History of myo/pericarditis * Left ventricle systolic dysfunction * Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency) * History of sinus node dysfunction or high-grade AV nodal block * History of aborted sudden cardiac death or cardiac arrest * Current seizure disorder on AED * Pregnant/Breast-feeding * Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised. Exclusion Criteria - Stratum C: * All genotypes of SCD * Diagnosed with three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography) * Anemia of grade 2 or worse (per CTCAE v5.0) at study visit 1 * Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina * Individuals with history of VT/VF or SVT * Previous cardiac surgery * Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect) * Stenotic valvular disease or left main coronary artery stenosis * History of myo/pericarditis * Left ventricle systolic dysfunction * Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency) * History of sinus node dysfunction or high-grade AV nodal block * History of aborted sudden cardiac death or cardiac arrest * Current seizure disorder on AED * Pregnant/Breast- feeding * Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.